›Publications›Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study. Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study. Auteurs : Morland D, Kanagaratnam L, Hubelé F, Toussaint E, Choquet S, Kas A, Caquot PA, Haioun C, Itti E, Leprêtre S, Decazes P, Bijou F, Schwartz P, Jacquet C, Chauchet A, Matuszak J, Kamar N, Payoux P, Durot E. Revue : Hemasphere Année : 2023 Groupe : QuantIF ← Retour aux publications